#United States #Chicago #Cancer Diagnostics #Creatv Bio #ASCO 2026

Creatv Bio Presents Significant Data at ASCO 2026

Creatv Bio, a division of Creatv MicroTech, Inc., is gearing up to present groundbreaking clinical data at the highly anticipated ASCO 2026 Annual Meeting, taking place in Chicago from May 29 to June 2, 2026. The company is set to showcase one poster presentation alongside four poster abstracts developed in collaboration with various pharmaceutical partners, demonstrating its commitment to advancing cancer diagnostic technologies.

The focal point of Creatv's presentation will be an abstract titled Monitoring blood-based biomarkers as early predictors of progression-free survival. This study is part of a randomized trial, Bria-ABC, focused on advanced metastatic breast cancer. The presentation is scheduled for May 30, 2026, from 1:30 PM to 4:30 PM CDT, under the session titled Developmental Therapeutics—Immunotherapy. Located at Poster Board 442, this presentation aims to provide insights into how blood-based biomarkers can predict patient outcomes.

In addition to the primary presentation, Creatv Bio will unveil four other poster abstracts that highlight their partnerships with notable companies such as BriaCell, a clinical-stage immuno-oncology company, and CytoDyn, renowned for their innovative cancer treatments. Together, they aim to shed light on various aspects of cancer treatment:

1. Monitoring PD-L1 expression in circulating cancer-associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors (Abstract e14535)
2. Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy (Abstract e15525)
3. Safety and 5-year survival following treatment with leronlimab plus physician's choice combination therapy in patients with metastatic triple-negative breast cancer (Abstract e14535)
4. Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC) (Abstract e13109)

Creatv Bio’s prominent LifeTracDx® blood test, referenced in these studies, plays a vital role as a companion and complementary diagnostic tool. It provides continuous monitoring, enabling pharmaceutical companies to optimize treatment strategies and enhance patient care.

About Creatv Bio

Creatv Bio operates as a CLIA-certified cancer diagnostics company, dedicated to delivering laboratory testing services to pharmaceutical entities, research partners, and patients involved in investigational studies. The LifeTracDx® test is under ongoing research to validate its efficacy further, primarily focusing on evaluating circulating biomarkers within oncology.

While the assay is not intended for clinical diagnosis, its research applications are instrumental in supporting translational and exploratory studies that could reshape the landscape of cancer diagnostics.

For those interested in exploring more about their innovative tools and comprehensive research, Creatv invites you to visit their official website at creatvbio.com.

With this impressive slate of presentations and a commitment to advancing cancer diagnostics, Creatv Bio is set to make a significant impact at ASCO 2026, showcasing their leadership in the field and their dedication to improving patient outcomes.